ABSTRACT
Background Nearly every individual sustaining traumatic spinal cord injury receives multiple types and classes of medications to manage a litany of secondary complications. Prior clinical studies and evidence from animal models suggest that several of these medications could enhance or impede endogenous neurological recovery. However, there is a knowledge gap surrounding the spectrum of pharmacologic agents typically administered in the routine management of spinal cord injury.
Objective To systematically determine the types of medications commonly administered, alone or in combination, in the acute to subacute phase of spinal cord injury.
Methods We conducted an analysis of two largescale cohorts (the Sygen interventional trial and the SCIRehab observational cohort study) to determine what constitutes “ standards of acute pharmacological care” after spinal cord injury. Concomitant medication use, including dosage, timing and reason for administration, was tracked. Descriptive statistics were used to describe the medications administered within the first 60 days after spinal cord injury.
Results Across 2040 individuals with spinal cord injury, 775 unique medications were administered within the two months after injury. On average, patients enrolled in the Sygen trial received 9.9 ± 4.9 (range 0-34), 14.3 ± 6.3 (range 1-40), 18.6 ± 8.2 (range 0-58), and 21.5 ± 9.7 (range 0-59) medications within the first 7, 14, 30, and 60 days post-injury, respectively. Patients enrolled in the SCIRehab cohort study received on average 1.7 ± 1.7 (range 0-11), 3.7 ± 3.7 (range 0-24), 8.5 ± 6.3 (range 0-42), and 13.5 ± 8.3 (range 0-52) medications within the first 7, 14, 30, and 60 days post-injury, respectively. Polypharmacy was commonplace (up to 43 medications per day per patient). Approximately 10% of medications were administered acutely as prophylaxis (e.g., against the development of pain or infections).
Conclusions To our knowledge, this was the first time acute pharmacological practices have been comprehensively examined after spinal cord injury. Our study revealed a high degree of polypharmacy in the acute stages of spinal cord injury, with potential to both positively and negatively impact neurological recovery. This data may provide key insight to achieve better understanding of how the acute pharmacological management of spinal cord injury affects long-term recovery. All results can be interactively explored on the RXSCI web site (https://jutzelec.shinyapps.io/RxSCI/) and GitHub repository (https://github.com/jutzca/Acute-Pharmacological-Treatment-in-SCI/).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by research grants from the Swiss National Science Foundation (Ambizione Grant #PZ00P3_186101, Jutzeler), Wings for Life Research Foundation (#2017_044, Jutzeler and Kramer), and Craig H. Nielsen Foundation (Cragg and Jutzeler).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval for this study (secondary analysis) was received by an institutional ethical standards committee on human experimentation at the University of British Columbia. The original Sygen clinical trial (results published elsewhere) also received ethical approval, but was conducted before clinical trials were required to be registered (i.e., no clinicaltrial.gov identifier available). Each participating center of the SCIRehab study received institutional review board approval for this study and obtained informed consent from each patient (or their parent/guardian).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵δ Shared Senior Authorship
Contributions Catherine R. Jutzeler: Study concept/design, data entry, data cleaning, data analyses, interpretation of data, and drafting the manuscript Bobo Tong: Data cleaning, interpretation of data and revising the manuscript for intellectual content Lucie Bourguignon: Interpretation of data and revising the manuscript for intellectual content Elias Ronca: Interpretation of data and revising the manuscript for intellectual content Eric Bailey: Primary data collection, interpretation of data, and revising the manuscript for intellectual content Noam Y. Harel: Data cleaning, interpretation of data, and revising the manuscript for intellectual content Fred Geisler: Data cleaning, interpretation of data, and revising the manuscript for intellectual content Adam R. Ferguson: Interpretation of data, revising the manuscript for intellectual content Brian K. Kwon: Interpretation of data, revising the manuscript for intellectual content Jacquelyn J. Cragg: Interpretation of data, revising the manuscript for intellectual content Lukas Grassner: Study concept/design, interpretation of data, revising the manuscript for intellectual content John LK Kramer: study concept/design, interpretation of data, and revising the manuscript for intellectual content
Statistical Analyses completed by: Dr. Catherine Jutzeler (Swiss Federal Institute of Technology, ETH Zurich)
Study Funding: This study was funded by research grants from the Swiss National Science Foundation (Ambizione Grant #PZ00P3_186101, Jutzeler), Wings for Life Research Foundation (#2017_044, Jutzeler and Kramer), and Craig H. Nielsen Foundation (Cragg and Jutzeler).
Disclosures: CR. Jutzeler reports no disclosures relevant to the manuscript. B. Tong reports no disclosures. L. Bourguignon reports no disclosures relevant to the manuscript. E. Ronca reports no disclosures relevant to the manuscript. E. Bailey reports no disclosures relevant to the manuscript. NY. Harel reports no disclosures relevant to the manuscript. F. Geisler reports no disclosures relevant to the manuscript. AR. Ferguson reports no disclosures relevant to the manuscript. BK. Kwon reports no disclosures relevant to the manuscript. JJ. Cragg reports no disclosures relevant to the manuscript. L. Grassner reports no disclosures relevant to the manuscript. JLK. Kramer reports no disclosures relevant to the manuscript.
Email addresses of co-authors: Bobo Tong: 310bobotong{at}gmail.com
Lucie Bourguignon: Lucie.Bourguignon{at}bsse.ethz.ch
Elias Ronca: elias.ronca{at}paraplegie.ch
Eric Bailey: Ebailey4{at}student.touro.edu
Noam Y. Harel: noam.harel{at}mountsinai.org
Fred Geisler: fgeisler{at}gmail.com
Adam Ferguson: Adam.Ferguson{at}ucsf.edu
Brian Kwon: brian.kwon{at}ubc.ca
Jacquelyn J. Cragg: jacquelyn.cragg{at}icord.org
Lukas Grassner: lukas.grassner{at}gmail.com
John L.K. Kramer: kramer{at}icord.org
Data Availability
Full anonymized data of both data sources will be shared at the request from any qualified investigator (please contact the Corresponding Author). The code for the data analysis and visualization is available in our GitHub repository (https://github.com/jutzca/Acute-Pharmacological-Treatment-in-SCI/).
